9 04, 2021

TAmiRNA shares microRNA biomarker insights at FIDELIO training webinar

2021-04-12T11:17:54+02:00April 9th, 2021|aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, diabetes, microRNAs, microstructure, osteoporosis, Personalized medicine, type 2 diabetes mellitus|Comments Off on TAmiRNA shares microRNA biomarker insights at FIDELIO training webinar

TAmiRNA is a key partner in the EU-funded Innovative Training Network FIDELIO, which aims to train the next generation of scientists in tackling the challenges of bone fragility in diabetic patients. The  webinar "MicroRNAs: small RNAs with big potential as biomarkers and drug targets in bone diseases" is a one-hour session hosted by TAmiRNA founder and CEO Dr. Matthias Hackl. He show how microRNAs control gene expression in virtually all human cells and that miRNA expression changes during the onset and progression of (bone) disorders enabling applications as biomarkers and drug targets. He introduce the biological and methodical basics of microRNA research and discuss diagnostic and therapeutic applications of microRNAs in bone disease. [...]

19 01, 2021

Circulating miRNAs in bone health and disease

2021-01-19T10:00:05+01:00January 19th, 2021|aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, microstructure, osteoporosis, Personalized medicine|Comments Off on Circulating miRNAs in bone health and disease

We want to draw your attention to our latest review which appeared in the special issue on miRNAs in Bone Research in Bone. In this review, we summarize important molecular basics of microRNA function and release and provide recommendations for best (pre-)analytical practices and documentation standards for circulating microRNA research required for generating high quality data and ensuring reproducibility of results. We review how the genesis of bone-derived circulating microRNAs via release from osteoblasts and osteoclasts could contribute to the communication between these cells and summarize evidence from clinical research studies that have investigated the clinical utility of microRNAs as biomarkers in musculoskeletal disorders. While previous reviews have mainly focused on diagnosis of primary osteoporosis, we have [...]

24 11, 2020

microRNA-146a controls age-related bone loss

2020-11-24T09:00:05+01:00November 24th, 2020|aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, microstructure, osteoporosis, Personalized medicine|Comments Off on microRNA-146a controls age-related bone loss

We want to draw your attention to the latest publication in cooperation with TAmiRNA. The study identifies a novel and unexpected role of miR‐146a in bone homeostasis. miR‐146a increases with age and acts as an epigenetic molecular switch terminating bone accrual, leading to bone loss during aging by downregulating bone anabolic Wnt signaling. Conversely, loss of miR‐146a leads to continuous bone accrual during aging as a result of unrestricted bone anabolism and intact Wnt signaling. Therefore, miR‐146a crucially controls the temporal facet of bone homeostasis. "microRNA-146a controls age-related bone loss" Saferding V, Hofmann M, Brunner JS, et al. Aging Cell. 2020 Nov;19(11):e13244. doi: 10.1111/acel.13244. click here to read the story

18 11, 2019

MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis.

2019-12-10T11:19:14+01:00November 18th, 2019|biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, osteomiR, osteoporosis, Personalized medicine|Comments Off on MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis.

We want to draw your attention to the latest publication of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in AUVA Research Center, in cooperation with TAmiRNA GmbH, in Bone. "MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis." Kocijan R, Weigl M, Skalicky S, et al. Bone 2019 Volume 131, February 2020, 115104. https://doi.org/10.1016/j.bone.2019.115104 Take the chance and download the paper

7 11, 2019

Serum microRNA as novel biomarkers for osteoporotic vertebral fractures.

2020-01-10T10:32:08+01:00November 7th, 2019|biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, osteomiR, osteoporosis, Personalized medicine|2 Comments

We want to draw your attention to the latest publication of the Department of Oncology and Metabolism, University of Sheffield, United Kingdom, in cooperation with TAmiRNA GmbH, in Bone. "Serum microRNA as novel biomarkers for osteoporotic vertebral fractures." Zarecki P, Hackl M, Grillari J, et al. Bone 2019 Oct 24:115105. doi: 10.1016/j.bone.2019.115105. Specific circulating miRNAs reflect the presence of osteoporotic vertebral fractures in postmenopausal women. They are unlikely to reflect low BMD, and more likely changes in bone quality or fracture healing. Take the chance and download this paper by clicking here

18 09, 2019

TAmiRNA GmbH is part of the EU-funded Innovative Training Network FIDELIO

2019-12-09T09:21:39+01:00September 18th, 2019|biomarkers, bone diseases, diabetes, microRNAs, Personalized medicine|Comments Off on TAmiRNA GmbH is part of the EU-funded Innovative Training Network FIDELIO

Diabetes mellitus is a widespread metabolic disease, with negative/adverse effects on many organ systems. Diabetes also significantly affects bone health. An increased risk of bone fractures and impaired fracture healing has been observed in patients, but the mechanisms are not fully understood. In order to investigate the links between diabetes and the bone system, the EU project "FIDELIO" will run for four years starting October 2019. This European Training Network, coordinated by scientists from the Faculty of Medicine of the Technical University of Dresden, is funded by the EU Marie Skłodowska-Curie Actions program with a total of 3.8 million €. FIDELIO aims to train the next generation of scientists in order to tackle the challenges of diabetic [...]

21 03, 2018

Serum levels of bone-related microRNAs and their association to bone microstructure and histomorphometry

2019-10-16T09:22:50+02:00March 21st, 2018|biomarker, bone diseases, microRNAs, microstructure, standard tools|Comments Off on Serum levels of bone-related microRNAs and their association to bone microstructure and histomorphometry

We want to draw your attention to the latest publication of the VINFORCE research Group in cooperation with TAmiRNA GmbH, in Scientific Reports from Nature. “Bone-related circulating microRNAs miR-29b-3p, miR-550a-3p, and miR-324-3p and their association to bone microstructure and histomorphometry.” Scientific Reports, Volume 8,4867 (2018) MicroRNAs are promising new biomarkers for bone diseases. The findings enhance the potential value of circulating miRNAs as bone biomarkers and the clinical utility of miRNAs to reflect dynamic changes in bone formation and microstructure. Click here to read the study